Galapagos NV Announces That BioFocus DPI Has Signed An Integrated Drug Discovery Collaboration With Boehringer Ingelheim Corporation

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Galapagos (Euronext: GLPG) announced today that its BioFocus subsidiary signed a new collaboration agreement with Boehringer Ingelheim. Under the terms of the agreement, BioFocus will apply its extensive drug discovery services to an undisclosed target within Boehringer Ingelheim's drug discovery portfolio.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC